Skip to main content
. 2022 Jan 5;12:790415. doi: 10.3389/fimmu.2021.790415

Figure 9.

Figure 9

Isolation of peptide-purified antibodies (pAbs) from human serum. (A) Pepscan analysis of human serum sample #20Hu384 (obtained from a COVID-19 convalescent patient) prior to purification. (B) Purification principle. Serum #20Hu384 was submitted to peptide-affinity chromatography using immobilized PEP3, PEP71, PEP72 or PEP79. (C) Elution profiles during chromatography. The fractions with the highest concentrations were combined. (D) Pepscan analysis of the pAbs purified on columns with immobilized PEP3, PEP71, PEP72 or PEP79. The lowest panel shows the profile of the control sample containing late (low-protein) elution fractions (= fractions 8 and 9 from PEP79 column). The bars show the OD450 nm value. (E) Western blot analysis of S-plasmid transfected PK-15 cells shows binding of pAb-PEP3 to cleaved (S2) and full-length SARS-CoV-2 S. (F) Antibody titers of serum #20Hu384, the four pAbs and elution buffer in IPMA assays for SARS-CoV-2 S and N; HCoV-229E and -OC43; and FeCV.